The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer

Annals of Oncology

Volumn 16, Issue 4, 2005, Pages 579-584

  Weinfurt, Kevin P ^a   Li, Y ^a   Castel, L D ^a   Saad, F ^b   Timbie, J W ^a   Glendenning, G A ^c   Schulman, K A ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b NOTRE DAME HOSPITAL   (Canada)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antineoplastic agents; Bone neoplasms; Diphosphonates; Prostatic neoplasms; Quality of life; Research design

Indexed keywords

PLACEBO; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PAIN ASSESSMENT; PATHOLOGIC FRACTURE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; WELLBEING;

EID: 18144427879     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi122     Document Type: Article

References (20)

1. Berruti A, Dogliotti L, Bitossi R et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000; 164: 1248-1253.
2. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000; 88: 2989-2994.
3. Pelger RC, Soerdjbalie-Maikoe V, Hamdy NA. Strategies for management of prostate cancer-related bone pain. Drugs Aging 2001; 18: 899-911.
4. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
5. Atkins CD. Correspondence Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2003; 95: 332.
6. Rosenthal M. Correspondence Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2003; 95: 332.
7. Litwin MS, Hays RD, Fink A et al. Quality-of-life outcomes in men treated for localized prostate cancer. J Am Med Assoc 1995; 273: 129-135.
8. Villavicencio H. Quality of life of patients with advanced and metastatic prostatic carcinoma. Eur Urol 1993; 24(Suppl 2): 118-121.
9. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-579.
10. Esper P, Mo F, Chodak G et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997; 50: 920-928.
11. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23: 129-138.
12. Janjan NA, Payne R, Gillis T et al. Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. J Pain Symptom Manage 1998; 16: 171-178.
13. Jensen MP, Karoly P. Pain-specific beliefs, perceived symptom severity, and adjustment to chronic pain. Clin J Pain 1992; 8: 123-130.
14. Radbruch L, Loick G, Kiencke P et al. Validation of the German version of the Brief Pain Inventory. J Pain Symptom Manage 1999; 18: 180-187.
15. Euroqol Group. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990; 16: 199-208.
16. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-1108.
17. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer-Verlag 2000.
18. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edition. Hillsdale: Lawrence Erlbaum Assoc 1988.
19. Samsa G, Edelman D, Rothman ML et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999; 15: 141-155.
20. Weinfurt KP, Anstrom KJ, Castel LD et al. Effect of zoledronic acid on clinically meaningful changes in pain associated with metastatic prostate cancer. J Clin Oncol 2004; 22 (Suppl): 4680.